BACKGROUND: Hepatocyte transplantation (HT) has the potential to become a promising treatment to temporarily support liver function in patients with liver failure. METHODS: Two patients, who had already received a liver transplant (LT) in the past, with an end-stage liver disease due to recurrent hepatitis C virus cirrhosis, suffering acute-on-chronic liver failure while on the waiting list for an LT, received HT as a bridge to whole-organ retransplantation. After HT and during intensive care unit admission, blood tests and ammonia levels were determined every 12 and 24 h, respectively, before and after each hepatocyte infusion. RESULTS: The present study describes monitoring of analytical and clinical parameters and improvement of liver function following HT. In both patients, we managed to lower the blood ammonia levels and clinically improve the degree of hepatic encephalopathy, thus serving as a bridge to liver retransplantation in 1 patient. CONCLUSIONS: We believe that this therapy may be an alternative treatment in patients with chronic liver disease who suffer episodes of acute decompensation as a bridge to conventional LT.
BACKGROUND: Hepatocyte transplantation (HT) has the potential to become a promising treatment to temporarily support liver function in patients with liver failure. METHODS: Two patients, who had already received a liver transplant (LT) in the past, with an end-stage liver disease due to recurrent hepatitis C virus cirrhosis, suffering acute-on-chronic liver failure while on the waiting list for an LT, received HT as a bridge to whole-organ retransplantation. After HT and during intensive care unit admission, blood tests and ammonia levels were determined every 12 and 24 h, respectively, before and after each hepatocyte infusion. RESULTS: The present study describes monitoring of analytical and clinical parameters and improvement of liver function following HT. In both patients, we managed to lower the blood ammonia levels and clinically improve the degree of hepatic encephalopathy, thus serving as a bridge to liver retransplantation in 1 patient. CONCLUSIONS: We believe that this therapy may be an alternative treatment in patients with chronic liver disease who suffer episodes of acute decompensation as a bridge to conventional LT.
Authors: Jan Best; Paul Manka; Wing-Kin Syn; Laurent Dollé; Leo A van Grunsven; Ali Canbay Journal: Hepatobiliary Surg Nutr Date: 2015-02 Impact factor: 7.293
Authors: Eugenia Pareja Ibars; Miriam Cortes; Laia Tolosa; Maria José Gómez-Lechón; Slivia López; José Vicente Castell; José Mir Journal: World J Gastroenterol Date: 2016-01-14 Impact factor: 5.742
Authors: J Siefert; K H Hillebrandt; S Moosburner; P Podrabsky; D Geisel; T Denecke; J K Unger; B Sawitzki; S Gül-Klein; S Lippert; P Tang; A Reutzel-Selke; M H Morgul; A W Reske; S Kafert-Kasting; W Rüdinger; J Oetvoes; J Pratschke; I M Sauer; N Raschzok Journal: Cell Transplant Date: 2019-12-17 Impact factor: 4.064
Authors: Michaela Kaldenbach; Francisco Javier Cubero; Stephanie Erschfeld; Christian Liedtke; Christian Trautwein; Konrad Streetz Journal: PLoS One Date: 2014-06-30 Impact factor: 3.240